Akums Drugs and Pharmaceuticals
Market cap ₹10,964 Cr
- P/E
- 30.14
- Day range
- ₹710.70 – ₹724.00
- 52-week range
- ₹409.30 – ₹838.80
- Volume
- 1.41 L
- Open
- ₹711.00
- Prev close
- ₹716.60
Latest results · Q2 FY27(consolidated)Revenue ₹1,342 Cr+31.9%Profit ₹115 Cr+168.3%Margin 8.5%YoY vs the same quarter last year
No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.
AKUMS in NSE indices and F&O
Research profile
Composite 68 / 100Factor percentiles
Derived metrics
- Earn. yield
- 3.3%
- Graham no.
- ₹341.01
- vs Graham
- -52.4%
- ROE ÷ P/B
- 2.4%
- 12-1 mom.
- +66.7%
- Return / vol
- 1.92
- Magic Formula
- #321
- Piotroski
- 4/6
- FCF yield
- 8.7%
- PEG
- 0.18
Appears in 14 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 68 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.49 L Cr | 40.95 | 5.03 | 14.8% | 21.0% | 29.0% | 0.04 | +11.9% |
| Divi's LaboratoriesDIVISLAB | ₹2.93 L Cr | 87.19 | 16.88 | 16.2% | 22.0% | 43.0% | 0.00 | +35.4% |
| Torrent PharmaTORNTPHARM | ₹1.75 L Cr | 77.88 | 9.67 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Apollo HospitalsAPOLLOHOSP | ₹1.27 L Cr | 56.40 | 11.55 | 22.6% | 17.0% | 16.0% | 0.77 | +23.0% |
| Laurus LabsLAURUSLABS | ₹1.25 L Cr | 93.72 | 19.82 | 18.2% | 18.0% | 34.0% | 0.43 | +33.5% |
| Zydus LifesciencesZYDUSLIFE | ₹1.20 L Cr | 28.72 | 4.32 | 20.1% | 21.0% | 24.0% | 0.50 | +29.2% |
| Dr. Reddy's LabsDRREDDY | ₹1.17 L Cr | 41.63 | 2.97 | 11.6% | 13.0% | 20.0% | 0.19 | -1.5% |
| Akums Drugs and PharmaceuticalsAKUMS | ₹10,964 Cr | 30.14 | 3.32 | 8.0% | 15.0% | 15.0% | 0.03 | +31.8% |
| Sector median | ₹24,603 Cr | 43.68 | 5.46 | 15.1% | 17.0% | 24.0% | 0.17 | +22.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 6h agoHeadlines about Akums Drugs and Pharmaceuticals from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.
Key metrics
- P/E (TTM)
- 29.9
- Price / Book
- 3.21
- ROE (FY26)
- 8.0%
- ROCE (latest year)
- 15%
- Dividend yield
- 0.14%
Moving averages (NSE)
- 20-day
- ₹727.58
- Price below
- 50-day
- ₹759.26
- Price below
- 200-day
- ₹621.17
- Price above
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- DII
- Public
- FII
- Others
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Financial statements
| Line item | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,083 | 944 | 1,019 | 1,033 | 1,010 | 1,056 | 1,024 | 1,018 | 1,160 | 1,158 | 1,167 | 1,342 |
| YoY Sales growth | — | — | — | -13 | -7 | — | — | -2 | — | — | — | — |
| Expenses | 989 | 941 | 891 | 912 | 889 | 962 | 895 | 923 | 1,013 | 1,006 | 992 | 1,148 |
| Operating Profit | 93 | 3 | 128 | 121 | 121 | 94 | 129 | 94 | 147 | 152 | 175 | 195 |
| OPM % | 9% | 0.3% | 13% | 12% | 12% | 9% | 13% | 9% | 13% | 13% | 15% | 15% |
| Other Income | 10 | 10 | 7 | 17 | 19 | 26 | 27 | 32 | 16 | 34 | 30 | 29 |
| Interest | 12 | 12 | 13 | 12 | 5 | 5 | 23 | 23 | 24 | 24 | 25 | 26 |
| Depreciation | 32 | 34 | 34 | 35 | 45 | 40 | 37 | 38 | 40 | 40 | 41 | 43 |
| Profit before tax | 59 | -33 | 87 | 92 | 91 | 75 | 96 | 66 | 100 | 121 | 139 | 155 |
| Tax % | -229% | 20% | 30% | 27% | 27% | -99% | 32% | 35% | 32% | 33% | 27% | 26% |
| Net Profit | 195 | -39 | 61 | 67 | 66 | 150 | 65 | 43 | 68 | 81 | 101 | 115 |
| EPS in Rs | ₹13.15 | ₹-2.80 | ₹4.08 | ₹4.14 | ₹4.14 | ₹9.38 | ₹4.03 | ₹2.59 | ₹4.21 | ₹5.38 | ₹6.35 | ₹7.17 |
From company filings, updated 19 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
-4 days since Mar 2021
+17 days since Mar 2021
+13 days since Mar 2021
-1 days since Mar 2021
0 days since Mar 2021
Strengths, risks & growth
Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services. [1]
Strengths
- Company is almost debt free.
Risks
- Stock is trading at 3.22 times its book value
- The company has delivered a poor sales growth of 9.87% over past five years.
- Company has a low return on equity of 9.89% over last 3 years.
Compounded Sales Growth
- 10 Years
- +10%
- 5 Years
- +10%
- 3 Years
- +6%
- TTM
- +18%
Compounded Profit Growth
- 10 Years
- +16%
- 5 Years
- +16%
- 3 Years
- +29%
- TTM
- +23%
Stock Price CAGR
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- 1 Year
- +69%
Return on Equity
- 10 Years
- —
- 5 Years
- +6%
- 3 Years
- +10%
- Last Year
- +8%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 75.26% | 75.26% | 75.26% | 75.26% | 0.00 pp |
| FII | 1.14% | 1.38% | 1.91% | 4.50% | +2.59 pp |
| DII | 14.41% | 14.36% | 13.44% | 11.09% | -2.35 pp |
| Public | 6.45% | 6.29% | 6.67% | 6.42% | -0.25 pp |
| Others | 2.73% | 2.73% | 2.73% | 2.73% | 0.00 pp |
Filed with NSE for Sept 2026: promoters 75.26%, public 22.01%
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 7.79% (-2.25 pp)- Promoters77.4%
- Foreign institutions4.6%
- Mutual funds7.8%
- Insurance0.1%
- Other domestic institutions3.5%
- Retail5.0%
- Others1.6%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| Franklin India Opportunities Fund | 1.75% | 2.02% | +0.23 pp |
| Franklin India Small Cap Fund | 1.40% | 1.16% | +0.20 pp |
| Bandhan Small Cap Fund | 1.17% | 0.37% | -0.01 pp |
| ICICI Pru Healthcare Fund | 1.06% | 1.65% | -0.24 pp |
| Nippon India Pharma Fund | 0.89% | 1.09% | +0.09 pp |
Scorecard
- Performance
- Low
- Valuation
- High
- Growth
- Avg
- Profitability
- High
- Entry point
- Good
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.
Risk & trend
From 292 daily sessions to 18 Nov 2026.
Risk
- Volatility (1Y)
- 33.0%
- Downside volatility
- 29.0%
- Worst 5% of days
- 3.0%
- Average of that tail
- 3.9%
- Max drawdown (1Y)
- 18.7%
- Below its peak
- 13.0%
Against the market
- Beta vs Nifty 50
- 0.85
- Correlation
- 0.35
- Relative strength (3M)
- -7.6%
- ATR (14)
- 3.9%
Return
- Return 1M
- -2.1%
- Return 3M
- -3.7%
- Return 6M
- +37.8%
- Return 1Y
- +63.2%
- vs 200-day average
- +15.3%
Momentum
- RSI (14)
- 42.5
- MACD histogram
- -0.94
- Stochastic %K
- 5.7
- ADX (14)
- 22.2
- +DI / −DI
- 23.1 / 23.0
- Money flow index
- 64.7
Participation
- Delivery (20d avg)
- 47.6%
- vs its 60-day baseline
- -3.1 pts
- Volume vs 20-day
- -0.5σ
- Close vs day's VWAP
- -0.4%
- 52-week position
- 74 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 30 Sept 2026.
Piotroski F-Score
4 of 6 tested
- Return on assets positive — passed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — passed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — failed
- Current ratio improving — failed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — passed
- Asset turnover improving — passed
- Free cash flow
- ₹951 Cr
- FCF yield
- 8.7%
- Cash conversion
- 4.61
- Accruals ratio
- -0.170
- Net debt
- -₹67 Cr
- Net debt / equity
- -0.02
- EV / sales
- 2.26
- PEG
- 0.18
- Capex intensity
- 5.3%
- Revenue CAGR
- 31.9%
- Profit CAGR
- 168.3%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Corporate actions
- dividend₹2.00
Dividend - Re 1 Per Share/Special Dividend - Rs 2 Per Share
3 Jul 2026ex-date
Company announcements
Intimation of Schedule of the Institutional Investors Meets
Intimation of Schedule of Investors/Analysts Meet
Intimation of ESG Rating
Intimation of Schedule of the Investors/Analysts Meet
Akums Drugs and Pharmaceuticals Limited has informed the exchange about an update on schedule of the Investors/ Analysts Meet to be held on August 25, 2026
Intimation of Schedule of the Investors/Analysts Meet
Transcript of Investors/Analysts conference call for the unaudited financial results of Q1 FY 27
Intimation of Schedule of the Investors/Analysts Meet to be held on August 14, 2026
Link of audio recording of Investors/Analysts Conference Call
Monitoring Agency Report for the quarter ended June 30, 2026
Investor Presentation
Un-audited Financial Results for the Quarter ended 30th June, 2026
Filed with BSE (scrip 544222); the last 45 days. Documents open at bseindia.com.
Documents
Annual reports
Earnings calls
- Nov 2026TranscriptSlidesRecording
- Aug 2026TranscriptSlidesRecording
- May 2026TranscriptSlides
- Feb 2026TranscriptSlides
- Nov 2025TranscriptSlidesRecording
- Aug 2025TranscriptSlidesRecording
Credit ratings
- Rating update · 10 Apr from icra
- Rating update · 9 Apr 2025 from icra
- Rating update · 31 Jan 2025 from icra
- Rating update · 9 Oct 2024 from icra
- Rating update · 8 Sep 2023 from icra
- Rating update · 30 Jun 2022 from icra
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 3 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Akums Drugs and Pharmaceuticals: common questions
Answered from the figures on this page.